世界のホスホジエステラーゼタイプ5（PDE5）阻害剤市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5948 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、ホスホジエステラーゼタイプ5（PDE5）阻害剤の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（シルデナフィル、タダラフィル、アバナフィル、バルデナフィル）、用途別市場規模（病院、小売薬局、オンライン薬局、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・ホスホジエステラーゼタイプ5（PDE5）阻害剤の市場動向 ・企業の競争状況、市場シェア ・ホスホジエステラーゼタイプ5（PDE5）阻害剤の種類別市場規模と予測2016-2027（シルデナフィル、タダラフィル、アバナフィル、バルデナフィル） ・ホスホジエステラーゼタイプ5（PDE5）阻害剤の用途別市場規模と予測2016-2027（病院、小売薬局、オンライン薬局、その他） ・ホスホジエステラーゼタイプ5（PDE5）阻害剤の北米市場規模2016-2027（アメリカ、カナダ） ・ホスホジエステラーゼタイプ5（PDE5）阻害剤の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・ホスホジエステラーゼタイプ5（PDE5）阻害剤のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・ホスホジエステラーゼタイプ5（PDE5）阻害剤の中南米市場規模2016-2027（メキシコ、ブラジル） ・ホスホジエステラーゼタイプ5（PDE5）阻害剤の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Eli Lilly、Pfizer、Bayer、Novartis AG、Merck、GlaxoSmithKline plc、Roche、AstraZeneca、BaiYunShan General Factory、SK Chemicals、Teva Pharma、Dong-A ST、Metuchen Pharma、Seoul Pharma、Vectura Group） ・結論

Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) is a drug used to block degradation of cgmp-specific phosphodiesterase type 5 (PDE5) loop GMP in smooth muscle cell lining supplying blood vessels to various tissues.These drugs dilate the cavernous penis, promote erections with sexual stimulation, and are used to treat erectile dysfunction (ED).Sildenafil is the first effective oral therapy for ED.Because PDE5 is also present in the wall of the smooth muscle arterioles of the inner lung, sildenafil and tadalafil dilate these vessels and are FDA approved for the treatment of pulmonary hypertension.

Market Analysis and Insights: Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market
The global Phosphodiesterase Type 5 (PDE5) Inhibitor market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Phosphodiesterase Type 5 (PDE5) Inhibitor market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Phosphodiesterase Type 5 (PDE5) Inhibitor market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Phosphodiesterase Type 5 (PDE5) Inhibitor market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Phosphodiesterase Type 5 (PDE5) Inhibitor market.

Global Phosphodiesterase Type 5 (PDE5) Inhibitor Scope and Market Size
Phosphodiesterase Type 5 (PDE5) Inhibitor market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Phosphodiesterase Type 5 (PDE5) Inhibitor market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Sildenafil
Tadalafil
Avanafil
Vardenafil

Segment by Application
Hospital
Retail Pharmacy
Online Pharmacies
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Eli Lilly
Pfizer
Bayer
Novartis AG
Merck
GlaxoSmithKline plc
Roche
AstraZeneca
BaiYunShan General Factory
SK Chemicals
Teva Pharma
Dong-A ST
Metuchen Pharma
Seoul Pharma
Vectura Group

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Sildenafil
1.2.3 Tadalafil
1.2.4 Avanafil
1.2.5 Vardenafil
1.3 Market by Application
1.3.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacies
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Perspective (2016-2027)
2.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Growth Trends by Regions
2.2.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Historic Market Share by Regions (2016-2021)
2.2.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Regions (2022-2027)
2.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Industry Dynamic
2.3.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Trends
2.3.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Drivers
2.3.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Challenges
2.3.4 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Revenue
3.1.1 Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Revenue (2016-2021)
3.1.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Players (2016-2021)
3.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue
3.4 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Concentration Ratio
3.4.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue in 2020
3.5 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players Head office and Area Served
3.6 Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Product Solution and Service
3.7 Date of Enter into Phosphodiesterase Type 5 (PDE5) Inhibitor Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Phosphodiesterase Type 5 (PDE5) Inhibitor Breakdown Data by Type
4.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Historic Market Size by Type (2016-2021)
4.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Type (2022-2027)

5 Phosphodiesterase Type 5 (PDE5) Inhibitor Breakdown Data by Application
5.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Historic Market Size by Application (2016-2021)
5.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2016-2027)
6.2 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type
6.2.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021)
6.2.2 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027)
6.2.3 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2027)
6.3 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application
6.3.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021)
6.3.2 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027)
6.3.3 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2027)
6.4 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country
6.4.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2016-2021)
6.4.2 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2016-2027)
7.2 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type
7.2.1 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021)
7.2.2 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027)
7.2.3 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2027)
7.3 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application
7.3.1 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021)
7.3.2 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027)
7.3.3 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2027)
7.4 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country
7.4.1 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2016-2021)
7.4.2 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2016-2027)
8.2 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type
8.2.1 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2027)
8.3 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application
8.3.1 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2027)
8.4 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Region
8.4.1 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2016-2027)
9.2 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type
9.2.1 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021)
9.2.2 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027)
9.2.3 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2027)
9.3 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application
9.3.1 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021)
9.3.2 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027)
9.3.3 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2027)
9.4 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country
9.4.1 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2016-2021)
9.4.2 Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2016-2027)
10.2 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type
10.2.1 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2027)
10.3 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application
10.3.1 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2027)
10.4 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country
10.4.1 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Details
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.1.4 Eli Lilly Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
11.1.5 Eli Lilly Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.2.4 Pfizer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
11.2.5 Pfizer Recent Development
11.3 Bayer
11.3.1 Bayer Company Details
11.3.2 Bayer Business Overview
11.3.3 Bayer Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.3.4 Bayer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
11.3.5 Bayer Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Details
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.4.4 Novartis AG Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
11.4.5 Novartis AG Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.5.4 Merck Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
11.5.5 Merck Recent Development
11.6 GlaxoSmithKline plc
11.6.1 GlaxoSmithKline plc Company Details
11.6.2 GlaxoSmithKline plc Business Overview
11.6.3 GlaxoSmithKline plc Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.6.4 GlaxoSmithKline plc Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
11.6.5 GlaxoSmithKline plc Recent Development
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.7.4 Roche Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
11.7.5 Roche Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.8.4 AstraZeneca Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
11.8.5 AstraZeneca Recent Development
11.9 BaiYunShan General Factory
11.9.1 BaiYunShan General Factory Company Details
11.9.2 BaiYunShan General Factory Business Overview
11.9.3 BaiYunShan General Factory Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.9.4 BaiYunShan General Factory Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
11.9.5 BaiYunShan General Factory Recent Development
11.10 SK Chemicals
11.10.1 SK Chemicals Company Details
11.10.2 SK Chemicals Business Overview
11.10.3 SK Chemicals Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.10.4 SK Chemicals Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
11.10.5 SK Chemicals Recent Development
11.11 Teva Pharma
11.11.1 Teva Pharma Company Details
11.11.2 Teva Pharma Business Overview
11.11.3 Teva Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.11.4 Teva Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
11.11.5 Teva Pharma Recent Development
11.12 Dong-A ST
11.12.1 Dong-A ST Company Details
11.12.2 Dong-A ST Business Overview
11.12.3 Dong-A ST Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.12.4 Dong-A ST Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
11.12.5 Dong-A ST Recent Development
11.13 Metuchen Pharma
11.13.1 Metuchen Pharma Company Details
11.13.2 Metuchen Pharma Business Overview
11.13.3 Metuchen Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.13.4 Metuchen Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
11.13.5 Metuchen Pharma Recent Development
11.14 Seoul Pharma
11.14.1 Seoul Pharma Company Details
11.14.2 Seoul Pharma Business Overview
11.14.3 Seoul Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.14.4 Seoul Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
11.14.5 Seoul Pharma Recent Development
11.15 Vectura Group
11.15.1 Vectura Group Company Details
11.15.2 Vectura Group Business Overview
11.15.3 Vectura Group Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
11.15.4 Vectura Group Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
11.15.5 Vectura Group Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Sildenafil
Table 3. Key Players of Tadalafil
Table 4. Key Players of Avanafil
Table 5. Key Players of Vardenafil
Table 6. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Regions (2016-2021)
Table 10. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Regions (2022-2027)
Table 12. Phosphodiesterase Type 5 (PDE5) Inhibitor Market Trends
Table 13. Phosphodiesterase Type 5 (PDE5) Inhibitor Market Drivers
Table 14. Phosphodiesterase Type 5 (PDE5) Inhibitor Market Challenges
Table 15. Phosphodiesterase Type 5 (PDE5) Inhibitor Market Restraints
Table 16. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Players (2016-2021)
Table 18. Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor as of 2020)
Table 19. Ranking of Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Product Solution and Service
Table 23. Date of Enter into Phosphodiesterase Type 5 (PDE5) Inhibitor Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Type (2016-2021)
Table 27. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Application (2016-2021)
Table 31. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country (2022-2027) & (US$ Million)
Table 63. Eli Lilly Company Details
Table 64. Eli Lilly Business Overview
Table 65. Eli Lilly Phosphodiesterase Type 5 (PDE5) Inhibitor Product
Table 66. Eli Lilly Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
Table 67. Eli Lilly Recent Development
Table 68. Pfizer Company Details
Table 69. Pfizer Business Overview
Table 70. Pfizer Phosphodiesterase Type 5 (PDE5) Inhibitor Product
Table 71. Pfizer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
Table 72. Pfizer Recent Development
Table 73. Bayer Company Details
Table 74. Bayer Business Overview
Table 75. Bayer Phosphodiesterase Type 5 (PDE5) Inhibitor Product
Table 76. Bayer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
Table 77. Bayer Recent Development
Table 78. Novartis AG Company Details
Table 79. Novartis AG Business Overview
Table 80. Novartis AG Phosphodiesterase Type 5 (PDE5) Inhibitor Product
Table 81. Novartis AG Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
Table 82. Novartis AG Recent Development
Table 83. Merck Company Details
Table 84. Merck Business Overview
Table 85. Merck Phosphodiesterase Type 5 (PDE5) Inhibitor Product
Table 86. Merck Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
Table 87. Merck Recent Development
Table 88. GlaxoSmithKline plc Company Details
Table 89. GlaxoSmithKline plc Business Overview
Table 90. GlaxoSmithKline plc Phosphodiesterase Type 5 (PDE5) Inhibitor Product
Table 91. GlaxoSmithKline plc Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
Table 92. GlaxoSmithKline plc Recent Development
Table 93. Roche Company Details
Table 94. Roche Business Overview
Table 95. Roche Phosphodiesterase Type 5 (PDE5) Inhibitor Product
Table 96. Roche Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
Table 97. Roche Recent Development
Table 98. AstraZeneca Company Details
Table 99. AstraZeneca Business Overview
Table 100. AstraZeneca Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
Table 101. AstraZeneca Recent Development
Table 102. BaiYunShan General Factory Company Details
Table 103. BaiYunShan General Factory Business Overview
Table 104. BaiYunShan General Factory Phosphodiesterase Type 5 (PDE5) Inhibitor Product
Table 105. BaiYunShan General Factory Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
Table 106. BaiYunShan General Factory Recent Development
Table 107. SK Chemicals Company Details
Table 108. SK Chemicals Business Overview
Table 109. SK Chemicals Phosphodiesterase Type 5 (PDE5) Inhibitor Product
Table 110. SK Chemicals Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
Table 111. SK Chemicals Recent Development
Table 112. Teva Pharma Company Details
Table 113. Teva Pharma Business Overview
Table 114. Teva Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Product
Table 115. Teva Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
Table 116. Teva Pharma Recent Development
Table 117. Dong-A ST Company Details
Table 118. Dong-A ST Business Overview
Table 119. Dong-A ST Phosphodiesterase Type 5 (PDE5) Inhibitor Product
Table 120. Dong-A ST Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
Table 121. Dong-A ST Recent Development
Table 122. Metuchen Pharma Company Details
Table 123. Metuchen Pharma Business Overview
Table 124. Metuchen Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Product
Table 125. Metuchen Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
Table 126. Metuchen Pharma Recent Development
Table 127. Seoul Pharma Company Details
Table 128. Seoul Pharma Business Overview
Table 129. Seoul Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Product
Table 130. Seoul Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
Table 131. Seoul Pharma Recent Development
Table 132. Vectura Group Company Details
Table 133. Vectura Group Business Overview
Table 134. Vectura Group Phosphodiesterase Type 5 (PDE5) Inhibitor Product
Table 135. Vectura Group Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021) & (US$ Million)
Table 136. Vectura Group Recent Development
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type: 2020 VS 2027
Figure 2. Sildenafil Features
Figure 3. Tadalafil Features
Figure 4. Avanafil Features
Figure 5. Vardenafil Features
Figure 6. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application: 2020 VS 2027
Figure 7. Hospital Case Studies
Figure 8. Retail Pharmacy Case Studies
Figure 9. Online Pharmacies Case Studies
Figure 10. Other Case Studies
Figure 11. Phosphodiesterase Type 5 (PDE5) Inhibitor Report Years Considered
Figure 12. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Regions: 2020 VS 2027
Figure 15. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Regions (2022-2027)
Figure 16. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Players in 2020
Figure 17. Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue in 2020
Figure 19. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Type (2016-2021)
Figure 20. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Type (2022-2027)
Figure 21. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2016-2027)
Figure 23. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2016-2027)
Figure 24. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Country (2016-2027)
Figure 25. United States Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2016-2027)
Figure 29. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2016-2027)
Figure 30. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Country (2016-2027)
Figure 31. Germany Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Region (2016-2027)
Figure 41. China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2016-2027)
Figure 49. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2016-2027)
Figure 50. Latin America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Country (2016-2027)
Figure 51. Mexico Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Country (2016-2027)
Figure 57. Turkey Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Eli Lilly Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
Figure 61. Pfizer Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
Figure 62. Bayer Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
Figure 63. Novartis AG Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
Figure 64. Merck Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
Figure 65. GlaxoSmithKline plc Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
Figure 66. Roche Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
Figure 67. AstraZeneca Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
Figure 68. BaiYunShan General Factory Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
Figure 69. SK Chemicals Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
Figure 70. Teva Pharma Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
Figure 71. Dong-A ST Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
Figure 72. Metuchen Pharma Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
Figure 73. Seoul Pharma Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
Figure 74. Vectura Group Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2016-2021)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed

---